Abelson tyrosine kinase (c-Abl) is involved in various biological processes in neurodegenerative diseases and is an attractive target for anti-PD (Parkinson's disease) drug discovery. Based on our previous work, we designed several novel c-Abl inhibitors through a conformational constrained strategy and evaluated their pharmacological activities. Among them, compound A6 exhibited superior inhibitory activity against c-Abl than nilotinib in the homogenous time-resolved fluorescence (HTRF) assay. Furthermore, A6 displayed higher neuroprotective effects against SH-SY5Y cell death induced by MPP and lower cytotoxicity than that of nilotinib. Molecular modeling revealed that the 1H-pyrrolo[2,3-B]pyridine ring may contribute to the high affinity of A6 for binding to c-Abl. Collectively, these results suggest that A6 deserves further investigation as a c-Abl inhibitor for neurodegenerative disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2023.117532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2.
Eur J Pharmacol
December 2024
Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan; Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital, Taipei, 10507, Taiwan; Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan; Molecular Medicine Research Center, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan. Electronic address:
Multidrug resistance (MDR) remains a significant obstacle in cancer treatment, primarily attributable to the overexpression of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2 within cancer cells. These transporters actively diminish the effectiveness of cytotoxic drugs by facilitating ATP hydrolysis-dependent drug efflux, thereby reducing intracellular drug accumulation. Given the absence of approved treatments for multidrug-resistant cancers and the established benefits of combining tyrosine kinase inhibitors (TKIs) with conventional anticancer drugs, we investigate the potential of vodobatinib, a potent c-Abl TKI presently in clinical trials, to restore sensitivity to chemotherapeutic agents in multidrug-resistant cancer cells overexpressing ABCB1 and ABCG2.
View Article and Find Full Text PDFDevelopment of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase.
Nat Commun
December 2024
Institute of Physiological Chemistry, Faculty of Medicine, Philipps University of Marburg, Marburg, Germany.
Article Synopsis
- Mirror-image proteins made from D-amino acids are promising for therapy due to their stability and minimal immune reactions.
- Development involves creating D-target proteins, selecting L-binders via phage display, and synthesizing D-binders that interact with the natural L-targets.
- The study focuses on D-monobodies with strong binding to the D-SH2 domain of the BCR::ABL1 kinase, showing potential for therapeutic applications by inhibiting its activity and functioning well in biological settings.
Ph+ ALL: new approaches for upfront therapy.
Hematology Am Soc Hematol Educ Program
December 2024
Adult Leukemia Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Article Synopsis
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) mainly impacts adults and is known for poor treatment outcomes due to its resistance to traditional chemotherapy.
- The introduction of Imatinib, a tyrosine kinase inhibitor, has significantly improved the prognosis for Ph+ ALL patients by enhancing their chances of achieving remission and qualifying for stem cell transplantation.
- Recent advancements in understanding Ph+ ALL have led to the development of more effective treatments, such as additional TKIs, immunotherapy, and improved monitoring methods, paving the way for better management of the disease.
New biological markers in diagnosis and follow-up of brucellosis cases.
Diagn Microbiol Infect Dis
February 2025
Department of Immunology, Bursa Uludag University Faculty of Medicine, Bursa, Turkey. Electronic address:
Brucellosis remains a significant public health issue in some parts of the world. It is clear that new laboratory methods are needed to diagnose brucellosis. Currently, no test method meets the criteria of high specificity, sensitivity, reliability, and low cost for the diagnosis of brucellosis, which could also predict chronicity.
View Article and Find Full Text PDFBeyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.
PLoS Comput Biol
November 2024
Department of Chemistry and Biomedical Sciences, Linnaeus University, Kalmar, Sweden.
Resistance to therapy is a major clinical obstacle to treatment of cancer and communicable diseases. Drug selection in treatment of patients where the disease is showing resistance to therapy is often guided by IC50 or fold-IC50 values. In this work, through a model of the treatment of chronic myeloid leukaemia (CML), we contest using fold-IC50 values as a guide for treatment selection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!